Where local control still decides outcomes: dose escalation and adaptive planning, short-course versus long-course scheduling, ablative, intra-arterial and bone-seeking radiopharmaceutical techniques, and when radiotherapy can safely be withheld.
RT CHARM (Alliance A221505) randomized 898 patients to conventional postmastectomy radiation (50 Gy in 25 fractions) or hypofractionated radiation (42.56 Gy in 16 fractions) after mastectomy with planned or completed breast reconstruction. Among 825 evaluable patients, the 24-month reconstruction complication rate was 12.3% with hypofractionation vs 10.2% with conventional radiation (difference −2.1%, 95% CI −6.5% to 2.2%), meeting the prespecified 10% non-inferiority margin (p = 0.0001).
NRG-BR002 was a randomized phase II/III trial of 129 patients with oligometastatic breast cancer (125 eligible; 65 vs 60) comparing first-line systemic therapy alone with the same therapy plus ablation of all metastases by SBRT or surgery. At the phase II analysis (72 PFS events), median PFS was 23.0 months without ablation versus 19.5 months with ablation (HR 0.92; 95% CI, 0.57–1.47; 1-sided P = .36; stratified P = .42).
EXTEND was an investigator-initiated, multicenter, open-label, six-basket phase II randomized trial of metastasis-directed therapy (MDT) added to standard of care (SOC) in oligometastatic solid tumors. In the aggregated per-protocol population (n = 334; 166 vs 168), progression-free survival favored MDT + SOC: HR 0.54 (95% CI 0.41 to 0.72), P < .001, with median PFS 25.40 vs 14.00 months at a median follow-up of 53 months.
A prospective, 25-center registry analysis of 787 patients treated with laser interstitial thermal therapy (LITT) for primary or metastatic brain tumors — the largest such analysis to date — found that how completely a tumor is ablated, and how small it is to begin with, are the strongest drivers of survival after the procedure.
The phase 2 RADICAL trial (Alliance A031801) tested whether adding the bone-targeted radiopharmaceutical radium-223 to cabozantinib would reduce skeletal morbidity in metastatic renal cell carcinoma (mRCC) with bone metastases. The study closed early for futility after a prespecified interim analysis.
The Step 2 randomization of NRG Oncology/RTOG 0848, a phase III trial of 354 patients with resected pancreatic head adenocarcinoma, found that adding chemoradiotherapy (CXRT) to adjuvant chemotherapy did not significantly improve overall survival across the full study population.
The Phase II FLARE-RT trial used mid-treatment FDG-PET response to selectively boost radiation dose (to 74 Gy, peak >90 Gy) only in the roughly one-third of unresectable NSCLC patients whose tumors were not responding, while treating responders with standard 60 Gy chemoradiation.
Long-term follow-up (median exceeding 10 years) of NRG Oncology RTOG 0539 validates a risk-adapted meningioma strategy: observation after gross total or subtotal resection for low-risk (WHO grade 1) disease, and radiotherapy for intermediate- and high-risk disease.
The phase III STELLAR trial (NCT02533271) randomly assigned 591 patients with distal or middle-third locally advanced rectal cancer to a short-course radiotherapy-based total neoadjuvant therapy regimen (SCRT-TNT) or standard long-course chemoradiotherapy (CRT); this update reports 5-year outcomes at a median follow-up of 68.7 months.
Phase 3 TORCH trial (241 patients, two tertiary centers in China, enrolled 2015-2024) randomized adults with unresectable, liver-confined, intermediate-stage (BCLC stage B) hepatocellular carcinoma 1:1 to transarterial chemoembolization (TACE) plus sequential radiofrequency ablation versus TACE alone.
Multicenter, open-label, randomized phase 2 trial (TREASURE, AIO-TRK-0320) at 20 sites in Germany and Austria testing whether adding consolidative thoracic radiotherapy (TRT, 30 Gy in 10 fractions) to atezolizumab maintenance improves overall survival in extensive-stage small cell lung cancer (ES-SCLC) after induction chemoimmunotherapy; 96 patients screened, 68 randomized 1:1